Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Pharma & Biotech

Biotech: opportunities for economic complexity and a rewarding career

Australia's underwhelming 93rd rank on the Harvard Economic Complexity Index (ECI) reveals a pressing need for economic diversification.

With an over-reliance on agriculture and mining, we rank lowest among Organisation for Economic Co-operation and Development (OECD) nations.

Under-investment in biotech

Despite abundant natural resources, experts say the failure to invest in sunrise industries, like biotechnology, which contributes an annual revenue of just A$8 billion to the economy, could jeopardise Australia's long-term economic sustainability.

Encouragingly, government initiatives like National Science Week are fostering scientific innovation, identifying industries that can elevate Australia's economic complexity.

The National Health and Medical Research Council (NHMRC)-funded biomedical research has also placed Australia at the 10th position globally for research output, according to the prestigious Nature rankings.

The A$20 billion Medical Research Future Fund (MRFF) aims to transition this top-tier research into life-saving drugs and therapies.

The biotech sector is not just a field of innovation but a critical pillar for Australia's economic future.

It offers resilience against global economic volatility and creates opportunities for high-skilled employment. The time is ripe for leveraging Australia's current wealth to invest substantially in biotechnology, a sunrise industry with immense promise.

There are signs that the sector is opening up, post-pandemic – and not just because of the interest brought by the innovations that COVID-19 compelled corporations to deliver.

Careers in the sector

The pathway to a career in biotech is more assured, post-pandemic. While the COVID-19 years propelled virtual job fairs to the forefront, offering cost-effective, safe and wide-reaching platforms for both employers and prospective employees, these fairs are making a welcome return to the physical world.

Students and experts alike emphasise the irreplaceable value of in-person interactions for networking and gauging company culture.

This trend underlines a distinct difference between early talent and experienced professionals; the former find immense value in face-to-face interactions, reflecting a nuanced approach to recruitment in the biotech sector.

These shifts in recruitment strategies offer a comprehensive view of the biotech industry's adaptability and its commitment to attracting highly skilled talent, further solidifying its role as a critical pillar for Australia's economic future.

Besides direct interaction with recruiters, in-person events offer a platform for meaningful engagement with peers and alumni and serve as information hubs, allowing students to explore employers graduates had perhaps not considered before.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK